| Drug General Information |
| Drug ID |
D08GJH
|
| Former ID |
DCL000727
|
| Drug Name |
Blonanserin
|
| Synonyms |
Lonasen; Blonanserin [INN]; AD 5423; AD-5423; Blonanserin (JAN/INN); 2-(4-Ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine; 2-(4-Ethyl-1-piperazinyl)-4-(p-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine; 2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine
|
| Drug Type |
Small molecular drug
|
| Indication |
Schizophrenia [ICD9: 295; ICD10:F20]
|
Phase 3 |
[1],
[2]
|
|---|
| Company |
Dainippon
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C23H30FN3
|
| InChI |
InChI=1S/C23H30FN3/c1-2-26-13-15-27(16-14-26)23-17-21(18-9-11-19(24)12-10-18)20-7-5-3-4-6-8-22(20)25-23/h9-12,17H,2-8,13-16H2,1H3
|
| InChIKey |
XVGOZDAJGBALKS-UHFFFAOYSA-N
|
| CAS Number |
CAS 132810-10-7
|
| PubChem Compound ID |
|
| PubChem Substance ID |
7848239, 10241370, 12014539, 14755159, 29305337, 47731227, 48329041, 49958772, 50834549, 57341408, 85210029, 92718895, 93309642, 99299305, 103443179, 104047267, 104361634, 109693023, 124766870, 124772061, 124894573, 126573701, 126628409, 126651438, 126651852, 126669973, 126732498, 129746063, 134222317, 134339225, 135080521, 135916580, 137006969, 144206818, 162012053, 162172135, 162248934, 164836972, 179149822, 196106488, 196367532, 198982671, 210274889, 210280524, 211534961, 223366005, 223383025, 223657861, 226491379, 252160945
|
| Target and Pathway |
| Target(s) |
D(2) dopamine receptor |
Target Info |
Antagonist |
[1]
|
|---|
| 5-hydroxytryptamine 2A receptor |
Target Info |
Antagonist |
[1]
|
|
KEGG Pathway
|
Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Gap junction
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholismhsa04020:Calcium signaling pathway
|
|
Serotonergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathwayP04374:5HT2 type receptor mediated signaling pathway
|
|
Reactome
|
Dopamine receptors
|
|
G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors
|
|
G alpha (q) signalling events
|
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
Nicotine Activity on Dopaminergic NeuronsWP733:Serotonin Receptor 2 and STAT3 Signaling
|
|
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
|
SIDS Susceptibility Pathways
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCRs, Other
|
| References |
| REF 1 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7670). |
|---|
